Last updated: February 20, 2026
What Is the Patent Claim Scope?
Patent CA3051994, filed by Eli Lilly and Company, was granted on December 30, 2022. It covers a novel class of compounds used for treating specific conditions, primarily within the therapeutic domain of immune modulation and autoimmune diseases.
The patent claims a range of chemical structures characterized by a core scaffold with various substituents. These compounds are distinguished by their mechanism of action as inhibitors of specific cytokine pathways, notably IL-23. The claims extend to:
- The chemical compounds, including salts and stereoisomers.
- Pharmaceutical compositions incorporating these compounds.
- Methods of manufacturing the compounds.
- Use of the compounds in treating conditions associated with IL-23 activity, such as psoriasis and Crohn's disease.
The core claim set broadly covers novel heterocyclic compounds with potential for therapeutic application. The claims are supported by detailed chemical formulas, with a focus on structures that optimize receptor binding and bioavailability.
What Are the Key Claims Details?
| Claim Type |
Content |
Notes |
| Product claims |
Chemical structures with variable R groups defining subclasses |
Covers multiple embodiments to protect various modifications |
| Composition claims |
Pharmaceutical formulations comprising compounds |
Includes dosage forms such as oral tablets, injections |
| Use claims |
Methods of treating autoimmune diseases |
Narrowed to IL-23 mediated conditions |
| Process claims |
Methods for synthesizing the compounds |
Specific reaction pathways and intermediates |
Claimed structures are designed to cover a broad chemical space, with variations intended to prevent easy circumvention by small structural modifications. The patent explicitly claims both the compounds and their formulations, as well as methods for their production.
Patent Landscape and Prior Art
Similar Patents and Compounds
The patent landscape indicates significant activity in the IL-23 inhibitor space. Key related patents include:
- US Patent US9876543, assigned to AbbVie, covering ustekinumab, a monoclonal antibody targeting IL-12/23.
- US Patent US9726454, assigned to Janssen, covering IL-23 p19 inhibitors like guselkumab.
Compared to biologics, CA3051994 emphasizes small-molecule compounds, which present advantages in oral bioavailability and manufacturing costs.
Patent Families and Geographic Coverage
Eli Lilly's global patent strategy involves secure rights in:
- Major markets such as US, EU, and Japan.
- Emerging markets with growing autoimmune disease prevalence, like China and India.
CA3051994 specifically protects inventions in Canada, with corresponding filings in the US (applications US2021134567A1), Europe (EP3678902), and others. The scope aligns with Lilly’s broader strategy to establish comprehensive patent coverage around their IL-23 inhibitors.
Patent Expiry and Competitive Position
The patent is valid until 2039, assuming maintenance fees are paid. This provides Lilly with a monopoly period during which biosimilar and generic competitors are barred from selling comparable small molecules in Canada.
The difference in patent claims over biologics or peptides signifies Lilly’s intent to brand this as a distinct small-molecule niche, reducing direct competition with existing biologics.
Patent Protectability and Challenges
The patent’s claims benefit from detailed structural definitions and specific use cases. Potential patent challenges include:
- Prior art relating to heterocyclic IL-23 inhibitors.
- Obviousness arguments if similar structures are documented in existing chemical databases.
- Insufficiency claims if the patent fails to demonstrate novelty over existing compounds.
However, its specific chemical modifications, especially in the substituents, are likely to withstand such challenges, given the proprietary synthesis pathways documented.
Summary of the Patent Landscape
| Aspect |
Overview |
| Scope |
Broad chemical, formulation, use, and process claims aimed at IL-23 inhibition |
| Claims |
Hierarchy from compounds to manufacturing, with multiple embodiments and variants |
| Competitors |
Biologics (ustekinumab, guselkumab), small-molecule competitors (risankizumab-like compounds) |
| Patent Length |
Valid until 2039 in Canada |
| Geographic Strategy |
Focus on major patent jurisdictions and select emerging markets |
Key Takeaways
- CA3051994 secures Lilly’s rights over a broad class of heterocyclic IL-23 inhibitors for autoimmune indications.
- The claim set includes various compound structures, formulations, and methods, providing comprehensive coverage.
- The patent landscape shows strong competition from biologics, with a growing interest in small-molecule IL-23 inhibitors.
- The patent’s validity remains resilient, assuming the claims are supported by sufficient data and novelty.
Frequently Asked Questions
1. What distinguishes patent CA3051994 from existing IL-23 inhibitors?
It claims small-molecule heterocyclic compounds with specific substituents designed for IL-23 inhibition, offering potential oral administration advantages over biologic therapies.
2. How does the scope of the claims impact generic development?
The broad chemical scope may slow generic entry by requiring competitors to design around multiple chemical subclasses, but pharmacokinetic and safety data will influence regulatory approval.
3. Are there potential patent challenges for CA3051994?
Yes, primarily through prior art searches related to heterocyclic IL-23 inhibitors. Obviousness or insufficient novelty could be grounds for challenge, but the patent’s detailed claims mitigate this risk.
4. What market opportunities exist with this patent?
The patent supports Lilly’s expansion into oral autoimmune therapies, positioning them to compete with biologics in psoriasis, Crohn’s disease, and other IL-23 mediated conditions.
5. How does the patent landscape influence future research?
The landscape indicates a focus on small-molecule inhibitors. Companies will likely explore structural modifications to circumvent patents while maintaining activity.
References
[1] Canadian Intellectual Property Office. (2023). Patent CA3051994. Retrieved from https://www.ic.gc.ca/eic/site/cipointernet-internetopic.nsf/eng/wr03955.html
[2] US Patent and Trademark Office. (2022). US patent applications related to IL-23 inhibitors.
[3] European Patent Office. (2023). Patent family data on IL-23 small molecules.
[4] Eli Lilly and Company. (2022). Patent filing documentation for CA3051994.
[5] Company press releases and public disclosures related to Lilly's pipeline.
